↓ Skip to main content

Predictors of response to Infliximab in children with luminal Crohn's disease☆

Overview of attention for article published in Journal of Crohn's and Colitis Supplements, January 2014
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Predictors of response to Infliximab in children with luminal Crohn's disease☆
Published in
Journal of Crohn's and Colitis Supplements, January 2014
DOI 10.1016/j.crohns.2013.12.017
Pubmed ID
Authors

Zubin Grover, Rebecca Biron, Nicholas Carman, Peter Lewindon

Abstract

A significant proportion of patients with initial response to Inflximab (IFX), subsequently lose response (LOR). Multicentre paediatric studies report LOR in 33% to 50% with 3-5year follow-up. Our retrospective study examined durability of response and predictors of LOR.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 23%
Student > Ph. D. Student 9 13%
Other 6 9%
Student > Postgraduate 5 7%
Professor > Associate Professor 5 7%
Other 13 19%
Unknown 15 22%
Readers by discipline Count As %
Medicine and Dentistry 36 52%
Agricultural and Biological Sciences 3 4%
Computer Science 2 3%
Biochemistry, Genetics and Molecular Biology 1 1%
Nursing and Health Professions 1 1%
Other 3 4%
Unknown 23 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2014.
All research outputs
#17,285,036
of 25,373,627 outputs
Outputs from Journal of Crohn's and Colitis Supplements
#1,492
of 2,103 outputs
Outputs of similar age
#202,356
of 320,591 outputs
Outputs of similar age from Journal of Crohn's and Colitis Supplements
#28
of 43 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,103 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,591 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.